10 interventions in Pharmaceutical.
GLP-1 Receptor Agonists (Semaglutide, Tirzepatide)
Genuinely transformative cardiometabolic drugs with real mortality-relevant benefit in people with excess weight, but they are not validated longevity agents, and muscle loss plus lack of aging-specific outcome data temper the 'anti-aging miracle' framing. Powerful for the right person, not a geroprotector for the lean and healthy.
SGLT2 Inhibitors (Canagliflozin, Empagliflozin, Dapagliflozin)
Real, hard-endpoint mortality benefit in sick populations (heart/kidney disease) and a striking male-mouse lifespan result, but the sex-specific animal effect and lack of any healthy-human aging trial mean the leap to 'longevity drug for the well' is unearned.
Statins (in a Longevity Context)
Genuinely life-saving for cardiovascular risk, and preventing the #1 killer buys years, but that is targeted disease prevention, not aging modulation. Calling statins a 'longevity drug' conflates two different things: they lengthen life by stopping heart attacks, not by slowing the aging process.
Lithium (Low Dose)
Interesting invertebrate lifespan data and suggestive drinking-water epidemiology, but the mouse data showed healthspan-only (no lifespan) benefit and human evidence is purely correlational. A plausible hypothesis with no human aging trial. Not a validated intervention.
Metformin
The poster child of 'geroprotector' hype, but the human longevity case rests on confounded observational data, and the one clean signal in healthy people (blunted exercise benefit) cuts against it. Excellent diabetes drug; unproven and possibly counterproductive as a longevity supplement for metabolically healthy, fit adults.
17-Alpha-Estradiol
A fascinating mechanistic tool that keeps working in the ITP, but with zero human data and a hard male-only sex bias, it is a research compound, not a supplement anyone should be taking. Interesting biology, not a therapy.
Acarbose
Genuinely impressive and reproducible in male mice, which is why the ITP takes it seriously, but the sex bias is a red flag and there is zero human longevity evidence. A reasonable, cheap, low-risk bet, not a proven human intervention.
Rapamycin (Sirolimus)
The best-validated geroprotector in animals and the most credible pharmaceutical bet, but the human evidence is still thin: one small underpowered RCT that missed its primary endpoints. 'Proven to extend human lifespan' is false. 'Most promising, still unproven, needs the hard trials' is the honest read.
Senolytics: Dasatinib + Quercetin (D+Q)
The senescent-cell-clearance concept is real and D+Q genuinely reduces senescent-cell burden in humans, which is a landmark. But translating that into hard clinical benefit has so far mostly failed or underwhelmed, and dasatinib's toxicity makes self-experimentation reckless. Promising mechanism, unproven therapy.
Aspirin (Low Dose)
A clear case where a large rigorous RCT settled it: for healthy older adults chasing longevity, daily aspirin is net-harmful (more bleeding, no survival benefit, a worrying mortality signal). Useful drug for the right cardiovascular indication, wrong drug for general 'anti-aging.'